BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback